Interactions Between Cyclosporin and Lipid-Lowering Drugs

@article{sberg2012InteractionsBC,
  title={Interactions Between Cyclosporin and Lipid-Lowering Drugs},
  author={Anders {\AA}sberg},
  journal={Drugs},
  year={2012},
  volume={63},
  pages={367-378}
}
  • Anders Åsberg
  • Published 2012
  • Medicine
  • Drugs
    • Dyslipidaemia is more frequent in solid organ transplant recipients than in the general population, primarily as a result of immunosuppressive drug treatment. Both cyclosporin and corticosteroids are associated with dyslipidaemic adverse effects. In order to reduce the overall cardiovascular risk in these patients, lipid-lowering drugs have become widely used, especially HMG-CoA reductase inhibitors (statins). Cyclosporin, as well as most statins (lovastatin, simvastatin, atorvastatin and… CONTINUE READING
    View on Springer
    52 Citations
    10 Cite Background
    1 Cite Results
    3
    Twitter Mentions

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 52 CITATIONS, ESTIMATED 50% COVERAGE

    [Hypolipidemic treatment under special conditions: posttransplant and/or immunosuppressive therapy].

    Treatment of dyslipidemia in kidney transplantation.

    Effect of Atorvastatin on Cyclosporine Pharmacokinetics in Liver Transplant Recipients

    ERSPECTIVES IN CLINICAL HARMACOLOGY rug interactions with lipid-lowering rugs : Mechanisms and clinical relevance

    More Potent Lipid-Lowering Effect by Rosuvastatin Compared With Fluvastatin in Everolimus-Treated Renal Transplant Recipients

    Cytochrome P450-mediated cardiovascular drug interactions

    • André Scheen
    • Medicine
    • Expert opinion on drug metabolism & toxicology
    • 2011
    VIEW 2 EXCERPTS
    CITES BACKGROUND & RESULTS

    Cyclosporine A- and Tacrolimus-Mediated Inhibition of CYP3A4 and CYP3A5 In Vitro

    Cyclosporin A-Induced Hyperlipidemia

    The pros and the cons of mTOR inhibitors in kidney

    The pros and the cons of mTOR inhibitors in kidney transplantation

    VIEW 1 EXCERPT
    CITES BACKGROUND

    FILTER CITATIONS BY YEAR

    2004
    2020

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 71 REFERENCES

    Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine.

    VIEW 2 EXCERPTS

    Effects of Simvastatin and Pravastatin on Hyperlipidemia and Cyclosporin Blood Levels in Renal Transplant Recipients

    Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.

    VIEW 1 EXCERPT

    Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.

    VIEW 4 EXCERPTS
    HIGHLY INFLUENTIAL

    The interaction of fluvastatin and cyclosporin A in renal transplant patients.

    VIEW 1 EXCERPT

    Pharmacokinetics and Pharmacodynamics of Fluvastatin in Heart Transplant Recipients Taking Cyclosporine A

    VIEW 1 EXCERPT

    Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.

    • L Renders, I Mayer-Kadner, +5 authors Ingeborg A. Hauser
    • Medicine
    • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
    • 2001
    VIEW 3 EXCERPTS
    HIGHLY INFLUENTIAL

    Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients.

    VIEW 4 EXCERPTS
    HIGHLY INFLUENTIAL

    Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.

    VIEW 2 EXCERPTS
    HIGHLY INFLUENTIAL

    Clinical Pharmacokinetics of Fluvastatin

    VIEW 2 EXCERPTS